CPRX
Held · Bookmarked
0 · 0
portfolios · users
Platform exposure
—
13F filers
1
institution
Market cap
$3.8B
122M shares
52-week range
$19.05 – $32.56
91% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.40%
Easy to borrow
Price (6 mo)
Catalyst Pharmaceutical Inc.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
www.catalystpharma.com- Employees
- 182
- IPO / List date
- Nov 8, 2006
- HQ
- CORAL GABLES, FL
Held by traders on TradeandTell
No one on the platform currently holds CPRX.
Super investors & insiders
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 3,544,830 | $69.8M |
- Form 4 filed Jun 5, 2026↗
- Form 4 filed Feb 19, 2026↗
- Form 4 filed Jan 6, 2026↗
- Form 4 filed Jan 6, 2026↗
- Form 4 filed Dec 30, 2025↗
- Form 4 filed Dec 30, 2025↗
- Form 4 filed Dec 30, 2025↗
- Form 4 filed Dec 30, 2025↗
- Form 4 filed Dec 30, 2025↗
- Form 4 filed Dec 30, 2025↗
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
Recent trades on TradeandTell
No one on the platform has traded CPRX yet.
$CPRX chatter on StockTwits
$CPRX did anyone receive anything about the virtual meeting to vote on the merger?
View on StockTwits ↗$CPRX https://www.stocktitan.net/sec-filings/CPRX/defm14a-catalyst-pharmaceuticals-inc-merger-proxy-statement-91233ea639e8.html
View on StockTwits ↗
$CPRX Catalyst Pharmaceuticals (CPRX) may not be the wildest biotech name on Wall Street, but that may be its biggest advantage. With profits, revenue, and rare disease exposure, this small-cap healthcare stock offers a more stable twist on biotech investing. https://biotechhealthx.com/biotech-news/is-catalyst-pharmaceuticals-cprx-a-smart-rare-disease-stock-to-buy-for-long-term-growth/
View on StockTwits ↗
$ARQT $AUPH $CPRX $OCUL $TRVI From cancer cell therapy to rare disease treatments and eye-disease breakthroughs, these small-cap biotech stocks are chasing major medical markets. Here are 10 biotech companies drawing attention for their pipelines, revenue growth, and upside potential. https://biotechhealthx.com/biotech-news/top-5-small-cap-biotech-stocks-that-could-surge-100/
View on StockTwits ↗
$CPRX Is this company sold? Why such low amplitude of stock movements?
View on StockTwits ↗
$CPRX I miss the stability we had here, its scary out there right now lol
View on StockTwits ↗
$CPRX is there a point on keeping any shares invested and wait for the closing in 6 months?
View on StockTwits ↗$CPRX any update on shareholders votes on the buyout?
View on StockTwits ↗
$CPRX can’t believe I went all in at 32.55. I can’t time nothing right🤪
View on StockTwits ↗
RECAP 5/28 +Pos Comments: $ZS + Malcolm Ethridge $PUMP + Odeon Capital RECAP 5/28 -Neg Comments: $DLTR - Freedom Broker $CPRX - HC Wainwright $PHR - Piper Sandler
View on StockTwits ↗
RECAP 5/28 +Pos Comments: $ZS + Malcolm Ethridge $PUMP + Odeon Capital RECAP 5/28 -Neg Comments: $DLTR - Freedom Broker $CPRX - HC Wainwright $PHR - Piper Sandler Live Breaking trading news www.openoutcrier.com
View on StockTwits ↗
$CPRX What a beautiful chart. That April 2nd crossing of the 34 was an easy load day. 😘 👇🪇🕺
View on StockTwits ↗
$CPRX a fair price to me would be $31.50 per share plus the approximate $7 they have in cash.
View on StockTwits ↗
Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.